MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24-
-An 8% discontinuation rate was observed in the combined study population-
-Zandelisib and zanubrutinib combination therapy demonstrated 100% response rate in patients with r/r indolent B-cell malignancies; combination administered on an optimized dosing regimen with no additive toxicity to each agent alone-
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Rhizen Pharmaceuticals (associate company of Alembic Pharmaceuticals) announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ: TGTX), has secured US FDA accelerated
approval for the treatment of:
- adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received
at least one prior anti-CD20 based regimen, and
- adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least
three prior lines of systemic therapy.
Accelerated approval was granted for these indications, under a priority review (MZL), based on the
results of the Phase 2 UNITY-NHL Trial (NCT02793583); in MZL, an ORR of 49% with 16% complete